GF Fund Management
LXEO icon

GF Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

GF Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.68K Buy
1,681
+136
+9% +$616 ﹤0.01% 569
2026
Q2 		$7.19K Sell
1,545
-83
-5% -$449 ﹤0.01% 555
2026
Q1 		$9.34K Buy
1,628
+194
+14% +$1.38K ﹤0.01% 563
2025
Q4 		$14.2K Buy
1,434
+272
+23% +$2.48K ﹤0.01% 546
2025
Q3 		$7.72K Buy
1,162
+342
+42% +$1.65K ﹤0.01% 574
2025
Q2 		$3.3K Hold
820
– – ﹤0.01% 640
2025
Q1 		$2.84K Buy
820
+126
+18% +$558 ﹤0.01% 643
2024
Q4 		$4.57K Buy
+694
New +$5.47K ﹤0.01% 613

Other funds holding LXEO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

GF Fund Management's LXEO Position: Q3 2026 in Review

GF Fund Management increased its Lexeo Therapeutics (LXEO) stake by 8.8% in Q3 2026, buying an estimated $616 and bringing the position to 1,681 shares worth $5.68K. The position accounts for ﹤0.01% of the portfolio, ranked #569.

GF Fund Management first reported a position in LXEO in Q4 2024 and has held it in 8 quarters since. The position peaked at $14.2K in Q4 2025. 44 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • GF Fund Management held 1,681 shares of Lexeo Therapeutics worth $5.68K as of Q3 2026.
  • GF Fund Management bought 136 Lexeo Therapeutics shares in Q3 2026, an estimated $616.
  • Lexeo Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #569 holding.
  • GF Fund Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Lexeo Therapeutics position peaked at $14.2K in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.